Cedara introduces 3D plug-ins
Canadian software developer Cedara has released a suite of 3D software plug-in components for examining CT and MR images. The products, collectively called Cedara Vivace, allow equipment manufacturers wanting to offer advanced 3D visualization to easily
Canadian software developer Cedara has released a suite of 3D software plug-in components for examining CT and MR images. The products, collectively called Cedara Vivace, allow equipment manufacturers wanting to offer advanced 3D visualization to easily plug the new software into imaging workstations already installed in the field or into new medical imaging devices. In market previews, companies reported being able to plug Vivace into their products in less than a week. Cedara Vivace adapts to the look and feel of its host application. Once plugged in, the 3D software becomes an integral part of the workstation. The suite offers four distinct rendering modes: maximum intensity projection, minimum intensity projection, shaded volume, and unshaded volume, as well as multiplanar reformatting.
Strategies to Reduce Disparities in Interventional Radiology Care
March 19th 2025In order to help address the geographic, racial, and socioeconomic barriers that limit patient access to interventional radiology (IR) care, these authors recommend a variety of measures ranging from increased patient and physician awareness of IR to mobile IR clinics and improved understanding of social determinants of health.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Study: Monitoring of Prostate MRI Exams Could Lead to 75 Percent Reduction of Gadolinium Contrast
March 17th 2025While DCE MRI was deemed helpful in over 67 percent of cases in which it was used, researchers found that monitored prostate MRI exams, which facilitated a 75 percent reduction of DCE MRI sequences, had comparable sensitivity for prostate cancer as non-monitored exams.
